Opinion ID: 866346
Heading Depth: 3
Heading Rank: 1

Heading: A composition comprising about 0.2% timolol by

Text: weight and about 0.5% brimonidine by weight as the sole active agents, in a single composition. The other claims of the ’463 patent include additional limitations directed to the amount of BAK in the composition and to packaging material that indicates that the ALLERGAN v. SANDOZ 5 composition is useful for treating glaucoma or ocular hypertension by twice a day topical administration of the composition to a person’s eye. In their briefs, the parties generally treat the claims as a group and, with the exception of claim 4 of the ’149 patent, do not argue them individually. As such, with the exception of claim 4, we treat the claims collectively. Claim 4 of the ’149 patent is directed to reducing the daily number of doses of brimonidine without loss of efficacy by administering brimonidine in a fixed combination with timolol. Claim 4 reads as follows: 4. A method of reducing the number of daily topi- cal ophthalmic doses of brimondine administered topically to an eye of a person in need thereof for the treatment of glaucoma or ocular hypertension from 3 to 2 times a day without loss of efficacy, wherein the concentration of brimonidine is 0.2% by weight, said method comprising administering said 0.2% brimonidine by weight and 0.5% timolol by weight in a single composition.